NCT04009681View on ClinicalTrials.gov

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Metastasis
Interventions
DRUG

THOR-707

Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

DRUG

Checkpoint inhibitor

Pharmaceutical form: solution for IV administration; Route of administration: IV administration

DRUG

anti-EGFR antibody

Pharmaceutical form: solution for IV administration; Route of administration: IV administration

Trial Locations (24)

34232

Investigational Site Number-1004, Sarasota

37203

Investigational Site Number-1003, Nashville

75032

Investigational Site Number-1007, Dallas

77030

Investigational Site Number-1002, Houston

78229

Investigational Site Number-1001, San Antonio

80218

Investigational Site Number-1005, Denver

85250

Investigational Site Number-1008, Scottsdale

Unknown

Investigational Site Number-7002, Buenos Aires

Investigational Site Number-2004, New South Whales

Investigational Site Number-2001, Perth

Investigational Site Number-2002, Victoria

Investigational Site Number-2003, Victoria

Investigational Site Number- 6001, Santiago

Investigational Site Number-6002, Santiago

Investigational Site Number-4002, Singapore

Investigational Site-4001, Singapore

Investigational Site Number-5001, Barcelona

Investigational Site Number-5006, Barcelona

Investigational Site Number-5007, Barcelona

Investigational Site Number-5002, Madrid

Investigational Site Number-5003, Madrid

Investigational Site Number-5004, Madrid

Investigational Site Number-5005, Madrid

Investigational Site Number-5105, Madrid

All Listed Sponsors
lead

Synthorx, Inc, a Sanofi company

INDUSTRY